Crossing the blood–brain-barrier with viral vectors

Current Opinion in Virology

Volumn 21, Issue , 2016, Pages 87-92

  Fu, Haiyan ^a   McCarty, Douglas M ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PEPTIDE; VIRUS VECTOR; DRUG CARRIER;

ADENO ASSOCIATED VIRUS 9; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CELL TRANSPORT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; ENDOTHELIUM; GENE THERAPY; HUMAN; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; TIGHT JUNCTION; TRANSCYTOSIS; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PERMEABILITY; PHARMACOKINETICS; PROCEDURES; VIRUS;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PERMEABILITY; TRANSCYTOSIS; TRANSDUCTION, GENETIC; VIRUSES;

EID: 84984687919     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.08.006     Document Type: Review

References (47)

1. 1 Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D.J., Structure and function of the blood–brain barrier. Neurobiol Dis 37 (2010), 13–25.
2. 2 Hendricks, B.K., Cohen-Gadol, A.A., Miller, J.C., Novel delivery methods bypassing the blood–brain and blood–tumor barriers. Neurosurg Focus, 38, 2015, E10.
3. 3 Shawkat, H., Westwood, M., Mortimer, A., Mannitol: a review of its clinical uses. Contin Educ Anaesth Crit Care Pain 12 (2012), 82–85.
4. 4 Bynoe, M.S., Viret, C., Yan, A., Kim, D.G., Adenosine receptor signaling: a key to opening the blood–brain door. Fluids Barriers CNS, 12, 2015, 20.
5. 5 Langiu, M., Dadparvar, M., Kreuter, J., Ruonala, M.O., Human serum albumin-based nanoparticle-mediated in vitro gene delivery. PLOS ONE, 9, 2014, e107603.
6. 6 Fu, H., Muenzer, J., Samulski, R.J., Breese, G., Sifford, J., Zeng, X., McCarty, D.M., Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 8 (2003), 911–917.
7. 7 Louboutin, J.P., Chekmasova, A.A., Marusich, E., Chowdhury, J.R., Strayer, D.S., Efficient CNS gene delivery by intravenous injection. Nat Methods 7 (2010), 905–907.
8. 8 Nilaver, G., Muldoon, L.L., Kroll, R.A., Pagel, M.A., Breakefield, X.O., Davidson, B.L., Neuwelt, E.A., Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood–brain barrier disruption. Proc Natl Acad Sci U S A 92 (1995), 9829–9833.
9. 9• McCarty, D.M., DiRosario, J., Gulaid, K., Muenzer, J., Fu, H., Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 16 (2009), 1340–1352 Demonstrated that global neurodegenerative disease could be corrected through vascular gene delivery to the CNS in a mouse model of MPS IIIB. Mannitol was used to transiently disrupt the BBB prior to IV vector administration.
10. 10 Fu, H., Bartz, J.D., Stephens, R.L. Jr., McCarty, D.M., Peripheral nervous system neuropathology and progressive sensory impairments in a mouse model of Mucopolysaccharidosis IIIB. PLoS ONE, 7, 2012, e45992.
11. 11• Thevenot, E., Jordao, J.F., O'Reilly, M.A., Markham, K., Weng, Y.Q., Foust, K.D., Kaspar, B.K., Hynynen, K., Aubert, I., Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound. Hum Gene Ther 23 (2012), 1144–1155 Local disruption of the BBB could be targeted to small areas of the brain using the combined effect of MRI-guided focused ultrasound and IV administered microbubles. Subsequent IV administration of rAAV vector allowed gene delivery to the targeted area of the brain. This technology paves the way for highly localized gene delivery.
12. 12 Weber-Adrian, D., Thevenot, E., O'Reilly, M.A., Oakden, W., Akens, M.K., Ellens, N., Markham-Coultes, K., Burgess, A., Finkelstein, J., Yee, A.J., et al. Gene delivery to the spinal cord using MRI-guided focused ultrasound. Gene Ther 22 (2015), 568–577.
13. 13 Wang, S., Olumolade, O.O., Sun, T., Samiotaki, G., Konofagou, E.E., Noninvasive, neuron-specific gene therapy can be facilitated by focused ultrasound and recombinant adeno-associated virus. Gene Ther 22 (2015), 104–110.
14. 14 Lipsman, N., Mainprize, T.G., Schwartz, M.L., Hynynen, K., Lozano, A.M., Intracranial applications of magnetic resonance-guided focused ultrasound. Neurotherapeutics 11 (2014), 593–605.
15. 15 Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.C., Samulski, R.J., McCown, T.J., Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood–brain barrier (BBB). Mol Ther 18 (2010), 570–578.
16. 16 Maheshri, N., Koerber, J.T., Kaspar, B.K., Schaffer, D.V., Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24 (2006), 198–204.
17. 17 Jones, A.R., Shusta, E.V., Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res 24 (2007), 1759–1771.
18. 18 Beatty, M.S., Curiel, D.T., Chapter two — adenovirus strategies for tissue-specific targeting. Adv Cancer Res 115 (2012), 39–67.
19. 19 Tang, Y., Han, T., Everts, M., Zhu, Z.B., Gillespie, G.Y., Curiel, D.T., Wu, H., Directing adenovirus across the blood–brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Gene Ther 14 (2007), 523–532.
20. 20 Laakkonen, J.P., Engler, T., Romero, I.A., Weksler, B., Couraud, P.O., Kreppel, F., Kochanek, S., Transcellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitro. PLoS ONE, 7, 2012, e45977.
21. 21 Bevan, A.K., Duque, S., Foust, K.D., Morales, P.R., Braun, L., Schmelzer, L., Chan, C.M., McCrate, M., Chicoine, L.G., Coley, B.D., et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 19 (2011), 1971–1980.
22. 22 Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.M., Fyfe, J., Moullier, P., Colle, M.A., Barkats, M., Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17 (2009), 1187–1196.
23. 23 Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., Kaspar, B.K., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27 (2009), 59–65.
24. 24 Gray, S.J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S.R., Samulski, R.J., Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19 (2011), 1058–1069.
25. 25 Murrey, D.A., Naughton, B.J., Duncan, F.J., Meadows, A.S., Ware, T.A., Campbell, K.J., Bremer, W.G., Walker, C.M., Goodchild, L., Bolon, B., et al. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev 25 (2014), 72–84.
26. 26 Bell, C.L., Vandenberghe, L.H., Bell, P., Limberis, M.P., Gao, G.P., Van Vliet, K., Agbandje-McKenna, M., Wilson, J.M., The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 121 (2011), 2427–2435.
27. 27 Shen, S., Bryant, K.D., Brown, S.M., Randell, S.H., Asokan, A., Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286 (2011), 13532–13540.
28. 28 Yang, B., Li, S., Wang, H., Guo, Y., Gessler, D.J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S.S., et al. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther 22 (2014), 1299–1309.
29. 29 Mietzsch, M., Broecker, F., Reinhardt, A., Seeberger, P.H., Heilbronn, R., Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J Virol 88 (2014), 2991–3003.
30. 30• Fu, H., Dirosario, J., Killedar, S., Zaraspe, K., McCarty, D.M., Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood–brain barrier gene delivery. Mol Ther 19 (2011), 1025–1033 Global neurdegeneration halted by gene delivery across the BBB using rAAV9 in a mouse model of MPS IIIB. In addition to the CNS therapeutic effects, systemic gene delivery provided treatment for the significant somatic manifestions of the disease.
31. 31 Ruzo, A., Marco, S., Garcia, M., Villacampa, P., Ribera, A., Ayuso, E., Maggioni, L., Mingozzi, F., Haurigot, V., Bosch, F., Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 23 (2012), 1237–1246.
32. 32 Duncan, F.J., Naughton, B.J., Zaraspe, K., Murrey, D.A., Meadows, A.S., Clark, K.R., Newsom, D.E., White, P., Fu, H., McCarty, D.M., Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice. Mol Ther 23 (2015), 638–647.
33. 33 Gong, Y., Mu, D., Prabhakar, S., Moser, A., Musolino, P., Ren, J., Breakefield, X.O., Maguire, C.A., Eichler, F.S., Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Mol Ther 23 (2015), 824–834.
34. 34 Weismann, C.M., Ferreira, J., Keeler, A.M., Su, Q., Qui, L., Shaffer, S.A., Xu, Z., Gao, G., Sena-Esteves, M., Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan. Hum Mol Genet 24 (2015), 4353–4364.
35. 35 Chen, Y.H., Chang, M., Davidson, B.L., Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15 (2009), 1215–1218.
36. 36•• Choudhury, S.R., Fitzpatrick, Z., Harris, A.F., Maitland, S.A., Ferreira, J.S., Zhang, Y., Ma, S., Sharma, R.B., Gray-Edwards, H.L., Johnson, J.A., et al. In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy. Mol Ther, 2016 Capsid DNA from 11 different AAV serotypes was shuffled to produce a highly complex library of mutants which were selected for CNS delivery across the BBB. The most efficient capsid recovered from the CNS transduced cells in the brain after IV delivery at approximately 10-fold higher level than the benchmark AAV9 capsid.
37. 37 Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol Ther 24 (2016), 726–735.
38. 38 Munch, R.C., Janicki, H., Volker, I., Rasbach, A., Hallek, M., Buning, H., Buchholz, C.J., Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 21 (2013), 109–118.
39. 39 Warrington, K.H. Jr., Gorbatyuk, O.S., Harrison, J.K., Opie, S.R., Zolotukhin, S., Muzyczka, N., Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 78 (2004), 6595–6609.
40. 40•• Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34 (2016), 204–209 AAV9 capsid was modified by insertion of a random peptide library, and a powerful selection strategy was devised to amplify mutant capsids only after they had successfully crossed the BBB and actively transduced cells within the CNS. The result was a mutant capsid that transduced 40-fold more cells in the CNS than the parent AAV9 capsid.
41. 41 DiMattia, M.A., Nam, H.J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B.L., McKenna, R., Olson, N.H., Sinkovits, R.S., Potter, M., et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol 86 (2012), 6947–6958.
42. 42 Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., Carcenac, R., Astord, S., Pereira de Moura, A., Voit, T., et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 20 (2011), 681–693.
43. 43 Foust, K.D., Wang, X., McGovern, V.L., Braun, L., Bevan, A.K., Haidet, A.M., Le, T.T., Morales, P.R., Rich, M.M., Burghes, A.H., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28 (2010), 271–274.
44. 44 Passini, M.A., Bu, J., Roskelley, E.M., Richards, A.M., Sardi, S.P., O'Riordan, C.R., Klinger, K.W., Shihabuddin, L.S., Cheng, S.H., CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120 (2010), 1253–1264.
45. 45 Valori, C.F., Ning, K., Wyles, M., Mead, R.J., Grierson, A.J., Shaw, P.J., Azzouz, M., Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med, 2, 2010, 35ra42.
46. 46 Fu, H., Cataldi, M.P., Ware, T.A., Zaraspe, K., Meadows, A.S., Murrey, D.A., McCarty, D.M., Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery. Mol Ther Methods Clin Dev, 3, 2016, 16036.
47. 47 Meadows, A.S., Duncan, F.J., Camboni, M., Waligura, K., Montgomery, C., Zaraspe, K., Naughton, B.J., Bremer, W.G., Shilling, C., Walker, C.M., et al. A GLP-compliant toxicology and biodistribution study: systemic delivery of an rAAV9 vector for the treatment of Mucopolysaccharidosis IIIB. Hum Gene Ther Clin Dev 26 (2015), 228–242.